Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Amanda Wilson; Neloufar Rahai; Ekkehard Beck; Elisha Beebe; B. Conroy; Daina B. Esposito; Priya Govil; Hagit Kopel; Tianyi Lu; James A. Mansi; Morgan A. Marks; Katherine E. Mues; Rohan Shah; Michelle Skornicki; Tianyu Sun; Astra Toyip; Mitra Yousefi; David Martin; Andre B. Araujo

doi:10.1007/s40121-024-01091-1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wilson et al. (2024) studied this question.

synapsesocial.com/papers/69d900e27e3358c846d17e7d https://doi.org/10.1007/s40121-024-01091-1

View Full Paper

Ask AI

Bookmark

Share

Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Ask about this paper

Abstract

Discussion

Cite This Study

Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading